Tagged with Canada

Canada Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs Inc., his previous company, for CAD 3.2 billion, the cycling accident that left him brain-damaged but more committed than ever…

Canada Luc Boileau, president and CEO of INESSS, the Quebecois National Institute of Excellence in Health and Social Services, the region’s healthcare technology assessment (HTA) body, describes how his organization is adapting to the evolutions taking place in global healthcare and the synergies that exist between the separate Quebecois and Canadian…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Canada Professor Rémi Quirion, chief scientist of Québec, discusses his mandate, encourages interprovincial collaboration between Ontario and Québec in the life sciences sector and explains the importance of engaging with civil society through social media to promote the value of research. Rémi, your position might be considered rather unique and niche.…

Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…

Canada Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends within the country. Lyndal, you established Ipsen’s Canadian affiliate in 2015. First and foremost, what opportunity did Ipsen globally see…

Canada Dr. Gaétan Barrette, Minister of Health and Social Services for Quebec, recaps the ambitious healthcare reforms pertaining to system integration and primary care access he has implemented since assuming position in April 2014, the philosophy driving his reform style, and the advantages that Quebec boasts as a life sciences hub.…

Canada Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex and multifaceted health ecosystem, and her goal of bringing together all healthcare stakeholders in much-needed dialogue on how to improve…

Canada This graph shows Quebec’s R&D expenditure as a percentage of GDP, in comparison to other provinces in Canada, as well as other OECD countries.

InterMune Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a stable environment for Canadian companies to grow. You have had an extensive and varied career, with positions in the Canadian…

Ernst & Young LLP   Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada.   What do you see as the biggest challenges of life sciences clients in…

Agro-Food President of Biotalent Canada discusses the advantages of being wholly aligned with the government, why the BioTalent is a necessary link between talent and company, and what this means for the bio-economy of Canada. What was your initial mission two years ago upon arriving at Biotalent Canada, having previously worked…